UNSPSC 51291902: Alaproclate

This classification denotes an antidepressant agent with the molecular formula C13H18ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4R42570ZO, chemically known as 4-chlor-alpha,alpha-dimethylphenethyl (rs)-2-aminopropionat but generally known as alaproclate, which bears US NIH Compound Identifier 2081. Alaproclate comes in base and hydrochloride forms. European Medicines Agency schedules Alaproclate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05292MIG.

UNSPSC 51291902 Alaproclate is a Commodity code that captures pharmaceutical products state and local governments acquire through both direct procurement and cooperative purchasing vehicles, though recent opportunities show limited activity specifically under this code's nominal scope. State and local solicitations under this code involve purchase of generic multi-source pharmaceuticals, over-the-counter products, naloxone, and related health-support items distributed through authorized wholesalers or direct delivery to community health facilities. Issuing bodies include state health agencies (such as the Texas Health and Human Services Commission), county health departments (Seminole County, Florida), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance) that aggregate demand across participating jurisdictions. The work ranges from one-time competitive bids for specific pharmaceutical inventories to multi-year framework agreements that establish pricing and supply terms for manufacturers supplying through authorized distributors.

Recent activity appears concentrated in the South (Florida) and Midwest (Minnesota, with multistate reach to Oregon), with the Texas HHS Commission conducting early-stage market intelligence on direct-to-manufacturer prescription programs. Representative solicitations include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline (note: the due date appears to be a data error in the source); the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, to assess vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements; and Minnesota's MMCAP S1070000015802 RFP, posted January 20, 2026, with response deadline March 26, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), effective July 1, 2026. The MMCAP RFP emphasizes price competitiveness (75 percent weight), cGMP and Drug Supply Chain Security Act compliance, and mandatory insurance coverage including $5,000,000 commercial general liability per occurrence.